Leap Therapeutics Reports Promising Data from Colorectal Cancer Research
Leap Therapeutics, Inc. (NASDAQ: LPTX) recently revealed updated findings from Part B of their DeFianCe study, showcasing significant advancements in the treatment of colorectal cancer through their investigational therapy, sirexatamab. This groundbreaking biotech company focuses on pioneering targeted and immuno-oncology therapeutics, and these results mark a crucial milestone in their mission.
Key Findings on Efficacy and Patient Outcomes
The preliminary data indicates a statistically significant increase in the overall response rate (ORR) of 32% among second-line colorectal cancer (CRC) patients exhibiting high levels of DKK1 when undergoing treatment with sirexatamab in conjunction with bevacizumab and chemotherapy. Furthermore, patients in this group experienced a progression-free survival (PFS) duration that was 3.5 months longer than those in the control group.
Improved Outcomes for Treatment-Naïve Patients
Among patients who had not previously received anti-VEGF therapy, a remarkable 22% increase in ORR and an extended PFS lasting 2.6 months were observed. These insights provide strong support for the potential of sirexatamab to enhance therapeutic outcomes in CRC treatment.
Continued Patient Engagement Indicates Strong Future Potential
As of the last data cut, 34 patients continued to benefit from the sirexatamab Experimental Arm, compared to just 24 in the Control Arm. This upward trend in patient engagement sheds light on the promising nature of the treatment and its observed efficacy across different patient demographics.
Expert Insights from Leap Therapeutics
Dr. Cynthia Sirard, Chief Medical Officer of Leap, expressed optimism regarding the results, stating, "The updated data from Part B of the DeFianCe study presented today confirms that sirexatamab can generate significantly higher ORR and longer PFS in CRC patients who have high levels of DKK1 or who have not had prior anti-VEGF therapy, two exploratory populations with strong scientific rationale. We believe that there is a compelling opportunity to move forward with a registrational study for sirexatamab to confirm these results and bring a new therapy to patients with CRC."
DeFianCe Study Insights
Here are the highlights regarding overall patient responses and survival outcomes from the updated analysis:
- High DKK1 Levels: In patients with high levels of DKK1 (n=44), the Experimental Arm exhibited a statistically significant 32% higher ORR of 48.0% compared to 15.8% in the Control Arm. The median PFS was recorded at 9.36 months versus 5.88 months in the Control group.
- Treatment-Naïve Patients: For the cohort of patients who had not received prior anti-VEGF therapy (n=95), the Experimental Arm displayed a 22% higher ORR of 55.1% and median PFS was significantly longer at 10.94 months compared to 8.34 months.
- Overall Patient Population: Across the entire intent-to-treat population (n=188), the sirexatamab Experimental Arm presented improved ORR, indicating favorable trends in treatment responses.
Robust Development Plans and Market Potential
The clinical results strengthen Leap Therapeutics' case for a registrational Phase 3 trial, targeting second-line MSS CRC patients, particularly those with elevated levels of DKK1 or those lacking anti-VEGF treatment history. This presents a substantial opportunity, with an estimated 30,000 patients in the US alone classified as second-line treated CRC patients and over 160,000 in broader markets.
Leap Therapeutics aims to build on these promising findings by exploring new business development opportunities. Their leadership recognizes the potential of sirexatamab and is dedicated to delivering innovative solutions that could transform treatment pathways in colorectal cancer.
Upcoming Conference Call Details
To discuss these findings in greater detail, Leap's management will host a conference call today. Stakeholders and interested parties can access the event live and participate in the discussion about the significance of the updated data.
About Leap Therapeutics
Leap Therapeutics remains steadfast in its commitment to developing targeted and immuno-oncology therapies. The firm's lead product candidate, sirexatamab (DKN-01), is focused on targeting the DKK1 protein and is currently undergoing evaluation in various clinical settings, particularly for patients facing colorectal cancer.
Frequently Asked Questions
What was the purpose of the DeFianCe study?
The DeFianCe study aimed to evaluate the efficacy of sirexatamab in combination with bevacizumab and chemotherapy in colorectal cancer patients.
What significant outcomes were reported?
Notable outcomes included a statistically significant increase in overall response rates and progression-free survival among specific patient cohorts treated with sirexatamab.
Who is the Chief Medical Officer of Leap Therapeutics?
Dr. Cynthia Sirard serves as the Chief Medical Officer of Leap Therapeutics, providing leadership and insights on clinical strategies.
When will the conference call take place?
The conference call is scheduled for the same day the data was released, providing a platform for the management team to discuss the results.
What is Leap Therapeutics' main focus?
Leap Therapeutics focuses on developing innovative therapeutics aimed at oncological treatments, primarily targeting mechanisms relevant to colorectal cancer.
